Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

8.34GBp
5:03am EDT
Change (% chg)

0.16 (+1.92%)
Prev Close
8.18
Open
8.49
Day's High
8.49
Day's Low
8.01
Volume
2,176,905
Avg. Vol
9,536,215
52-wk High
11.50
52-wk Low
2.98

Select another date:

Thu, Jul 6 2017

Photo

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON, July 6 Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

BRIEF-Oxford Biomedica completes new $55 million debt facility

* Completed a new $55 million debt facility with Oaktree Capital Management - Strategic Credit Strategy

BRIEF-Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019

* Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019

BRIEF-Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses

* Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses

Select another date: